We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q1 Earnings
Read MoreHide Full Article
Wall Street analysts expect Globus Medical (GMED - Free Report) to post quarterly earnings of $0.55 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $586.66 million, up 112% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Globus Medical metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net Sales by Product Category- Enabling Technologies' should come in at $25.85 million. The estimate points to a change of +3.1% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales by Product Category- Musculoskeletal Solutions' reaching $560.30 million. The estimate indicates a year-over-year change of +122.7%.
The collective assessment of analysts points to an estimated 'Geographic Revenues- International' of $108.73 million. The estimate indicates a year-over-year change of +155.4%.
Analysts expect 'Geographic Revenues- United States' to come in at $479.99 million. The estimate suggests a change of +105% year over year.
Shares of Globus Medical have demonstrated returns of +0.2% over the past month compared to the Zacks S&P 500 composite's -1.6% change. With a Zacks Rank #2 (Buy), GMED is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Wall Street's Insights Into Key Metrics Ahead of Globus Medical (GMED) Q1 Earnings
Wall Street analysts expect Globus Medical (GMED - Free Report) to post quarterly earnings of $0.55 per share in its upcoming report, which indicates a year-over-year increase of 3.8%. Revenues are expected to be $586.66 million, up 112% from the year-ago quarter.
Over the past 30 days, the consensus EPS estimate for the quarter has remained unchanged. This demonstrates the covering analysts' collective reassessment of their initial projections during this period.
Before a company announces its earnings, it is essential to take into account any changes made to earnings estimates. This is a valuable factor in predicting the potential reactions of investors toward the stock. Empirical research has consistently shown a strong correlation between trends in earnings estimate revisions and the short-term price performance of a stock.
While investors typically rely on consensus earnings and revenue estimates to gauge how the business may have fared during the quarter, examining analysts' projections for some of the company's key metrics often helps gain a deeper insight.
Given this perspective, it's time to examine the average forecasts of specific Globus Medical metrics that are routinely monitored and predicted by Wall Street analysts.
According to the collective judgment of analysts, 'Net Sales by Product Category- Enabling Technologies' should come in at $25.85 million. The estimate points to a change of +3.1% from the year-ago quarter.
Analysts' assessment points toward 'Net Sales by Product Category- Musculoskeletal Solutions' reaching $560.30 million. The estimate indicates a year-over-year change of +122.7%.
The collective assessment of analysts points to an estimated 'Geographic Revenues- International' of $108.73 million. The estimate indicates a year-over-year change of +155.4%.
Analysts expect 'Geographic Revenues- United States' to come in at $479.99 million. The estimate suggests a change of +105% year over year.
View all Key Company Metrics for Globus Medical here>>>
Shares of Globus Medical have demonstrated returns of +0.2% over the past month compared to the Zacks S&P 500 composite's -1.6% change. With a Zacks Rank #2 (Buy), GMED is expected to beat the overall market performance in the near future. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>